KCT0000701已完成未知
Randomized, Open, 2-way cross over, Single dose study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male
Hanmi Pharm0 个研究点目标入组 68 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 50(Year)（—）
- 性别
- Male
入选标准
- •1. BMI: 18.0 - 27.0 kg/m2
- •2. Willingness to sign the written Informed Consent Form
排除标准
- •1.Evidence of clinically relevant pathology
- •2.History of relevant drug and food allergies
- •3.Positive screen on drugs of abuse
- •4.Participation in a drug study within 3months prior to drug administration.
研究者
相似试验
已完成
1 期
Pharmacokinetic study of two orally formulated modified release tablets of Ferrous Sulfate 325mg and Sodium Ascorbate 562.4 mg in healthy volunteers under fasting and fed conditions.AnaemiaBlood - AnaemiaACTRN12619000171112AFT Pharmaceuticals Ltd.25
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Rivaroxaban 20 mg Film-coated Tablet (XALT (20 MG TABLET)) and Reference Product (Xarelto) in Healthy Thai Volunteers under Fed ConditionsHealthy Thai VolunteersTCTR20210913004International Bio Service30
进行中（未招募）
不适用
A Randomized, Open, 2-way cross-over, Single dose study to Evaluate and Compare Safety and Pharmacokinetics of the HIP1302 and HGP1406 in Healthy Korean Male VolunteersKCT0001635Hanmi Pharm38
进行中（未招募）
1 期
Bioequivalence of rivaroxaban granules for oral suspension and rivaroxaban tabletsPrevention and treatment of thromboembolic disordersMedDRA version: 19.1Level: LLTClassification code 10043640Term: Thrombosis venousSystem Organ Class: 100000004866EUCTR2017-000648-16-DEBayer AG30
进行中（未招募）
1 期
Bioequivalence study of rivaroxaban granules for oral suspension and rivaroxaban tabletsPrevention and treatment of thromboembolic disordersMedDRA version: 19.1Level: LLTClassification code 10043640Term: Thrombosis venousSystem Organ Class: 100000004866EUCTR2017-000609-18-DEBayer AG30